Is Indaptus Therapeutics, Inc. (INDP) a Buy, Sell, or Hold?
NASDAQ : INDP
Indaptus Therapeutics, Inc. — News
$2.46 USD
-$0.07 (-2.77%)
- Volume
- 33.4K
- Average Volume
- 1.01M
- Market Capitalization
- $4.31M
- P/E Ratio
- -0.39
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $12.03
- Year Low
- $0.92
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.34
| Source | Headline |
|---|---|
|
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Indaptus Therapeutics, Inc. (Nasdaq: INDP) who held their shares prior to December 22, 2025. globenewswire.com - 2026-06-17 23:02:00 |
|
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, commented, “Following recent changes in executive management, the Company has conducted a review of its development programs, operating resources and ongoing corporate initiatives. globenewswire.com - 2026-05-15 07:00:00 |
